Literature DB >> 28923869

A Quasi-Experiment To Study the Impact of Vancomycin Area under the Concentration-Time Curve-Guided Dosing on Vancomycin-Associated Nephrotoxicity.

Natalie A Finch1, Evan J Zasowski2, Kyle P Murray1, Ryan P Mynatt1, Jing J Zhao1, Raymond Yost1, Jason M Pogue1, Michael J Rybak3,2,4.   

Abstract

Evidence suggests that maintenance of vancomycin trough concentrations at between 15 and 20 mg/liter, as currently recommended, is frequently unnecessary to achieve the daily area under the concentration-time curve (AUC24) target of ≥400 mg · h/liter. Many patients with trough concentrations in this range have AUC24 values in excess of the therapeutic threshold and within the exposure range associated with nephrotoxicity. On the basis of this, the Detroit Medical Center switched from trough concentration-guided dosing to AUC-guided dosing to minimize potentially unnecessary vancomycin exposure. The primary objective of this analysis was to assess the impact of this intervention on vancomycin-associated nephrotoxicity in a single-center, retrospective quasi-experiment of hospitalized adult patients receiving intravenous vancomycin from 2014 to 2015. The primary analysis compared the incidence of nephrotoxicity between patients monitored by assessment of the AUC24 and those monitored by assessment of the trough concentration. Multivariable logistic and Cox proportional hazards regression examined the independent association between the monitoring strategy and nephrotoxicity. Secondary analysis compared vancomycin exposures (total daily dose, AUC, and trough concentrations) between monitoring strategies. Overall, 1,280 patients were included in the analysis. After adjusting for severity of illness, comorbidity, duration of vancomycin therapy, and concomitant receipt of nephrotoxins, AUC-guided dosing was independently associated with lower nephrotoxicity by both logistic regression (odds ratio, 0.52; 95% confidence interval [CI], 0.34 to 0.80; P = 0.003) and Cox proportional hazards regression (hazard ratio, 0.53; 95% CI, 0.35 to 0.78; P = 0.002). AUC-guided dosing was associated with lower total daily vancomycin doses, AUC values, and trough concentrations. Vancomycin AUC-guided dosing was associated with reduced nephrotoxicity, which appeared to be a result of reduced vancomycin exposure.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  acute kidney injury; pharmacodynamics; pharmacokinetics; therapeutic drug monitoring; trough concentration

Mesh:

Substances:

Year:  2017        PMID: 28923869      PMCID: PMC5700348          DOI: 10.1128/AAC.01293-17

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  32 in total

1.  Are vancomycin trough concentrations adequate for optimal dosing?

Authors:  Michael N Neely; Gilmer Youn; Brenda Jones; Roger W Jelliffe; George L Drusano; Keith A Rodvold; Thomas P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2013-10-28       Impact factor: 5.191

2.  Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists.

Authors:  Michael J Rybak; Ben M Lomaestro; John C Rotschafer; Robert C Moellering; Willam A Craig; Marianne Billeter; Joseph R Dalovisio; Donald P Levine
Journal:  Clin Infect Dis       Date:  2009-08-01       Impact factor: 9.079

3.  Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin-tazobactam or cefepime.

Authors:  Diane M Gomes; Carmen Smotherman; Amy Birch; Lori Dupree; Bethany J Della Vecchia; Dale F Kraemer; Christopher A Jankowski
Journal:  Pharmacotherapy       Date:  2014-04-18       Impact factor: 4.705

4.  Can we guarantee less nephrotoxicity when vancomycin is administered by continuous infusion?

Authors:  Daniel Echeverría-Esnal; Mónica Marín-Casino; Alexandra Retamero; Santiago Grau
Journal:  Int J Antimicrob Agents       Date:  2016-04-25       Impact factor: 5.283

5.  Evaluation of a two-compartment Bayesian forecasting program for predicting vancomycin concentrations.

Authors:  K A Rodvold; R D Pryka; M Garrison; J C Rotschafer
Journal:  Ther Drug Monit       Date:  1989       Impact factor: 3.681

6.  Is peak concentration needed in therapeutic drug monitoring of vancomycin? A pharmacokinetic-pharmacodynamic analysis in patients with methicillin-resistant staphylococcus aureus pneumonia.

Authors:  Yosuke Suzuki; Kanako Kawasaki; Yuhki Sato; Issei Tokimatsu; Hiroki Itoh; Kazufumi Hiramatsu; Masaharu Takeyama; Jun-Ichi Kadota
Journal:  Chemotherapy       Date:  2012-11-07       Impact factor: 2.544

7.  Establishment of an AUC0-24 Threshold for Nephrotoxicity Is a Step towards Individualized Vancomycin Dosing for Methicillin-Resistant Staphylococcus aureus Bacteremia.

Authors:  R Chavada; N Ghosh; I Sandaradura; M Maley; S J Van Hal
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

8.  Vancomycin AUC24/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization.

Authors:  Jack Brown; Kristen Brown; Alan Forrest
Journal:  Antimicrob Agents Chemother       Date:  2011-11-28       Impact factor: 5.191

Review 9.  Continuous versus intermittent infusion of vancomycin in adult patients: A systematic review and meta-analysis.

Authors:  Jing-Jing Hao; Han Chen; Jian-Xin Zhou
Journal:  Int J Antimicrob Agents       Date:  2015-11-24       Impact factor: 5.283

Review 10.  Innovative approaches to optimizing the delivery of vancomycin in individual patients.

Authors:  Manjunath P Pai; Michael Neely; Keith A Rodvold; Thomas P Lodise
Journal:  Adv Drug Deliv Rev       Date:  2014-06-05       Impact factor: 15.470

View more
  46 in total

1.  Identification of Vancomycin Exposure-Toxicity Thresholds in Hospitalized Patients Receiving Intravenous Vancomycin.

Authors:  Evan J Zasowski; Kyle P Murray; Trang D Trinh; Natalie A Finch; Jason M Pogue; Ryan P Mynatt; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

2.  Should Therapeutic Monitoring of Vancomycin Based on Area under the Curve Become Standard Practice for Patients with Confirmed or Suspected Methicillin-Resistant Staphylococcus aureus Infection?

Authors: 
Journal:  Can J Hosp Pharm       Date:  2020-06-01

3.  Vancomycin Area Under the Curve and Acute Kidney Injury: A Meta-analysis.

Authors:  Doaa M Aljefri; Sean N Avedissian; Nathaniel J Rhodes; Michael J Postelnick; Kevin Nguyen; Marc H Scheetz
Journal:  Clin Infect Dis       Date:  2019-11-13       Impact factor: 9.079

4.  Prospective Trial on the Use of Trough Concentration versus Area under the Curve To Determine Therapeutic Vancomycin Dosing.

Authors:  Michael N Neely; Lauren Kato; Gilmer Youn; Lironn Kraler; David Bayard; Michael van Guilder; Alan Schumitzky; Walter Yamada; Brenda Jones; Emi Minejima
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

5.  Performance of Area under the Concentration-Time Curve Estimations of Vancomycin with Limited Sampling by a Newly Developed Web Application.

Authors:  Kazutaka Oda; Yumi Hashiguchi; Toshimi Kimura; Yasuhiro Tsuji; Kensuke Shoji; Yoshiko Takahashi; Kazuaki Matsumoto; Hideki Kawamura; Hideyuki Saito; Yoshio Takesue
Journal:  Pharm Res       Date:  2021-03-29       Impact factor: 4.200

6.  Population Pharmacokinetic Model for Vancomycin Used in Open Heart Surgery: Model-Based Evaluation of Standard Dosing Regimens.

Authors:  Saeed A Alqahtani; Abdullah S Alsultan; Hussain M Alqattan; Ahmed Eldemerdash; Turki B Albacker
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

7.  Vancomycin dosing and therapeutic drug monitoring practices: guidelines versus real-life.

Authors:  Tatjana Van Der Heggen; Franky M Buyle; Barbara Claus; Annemie Somers; Petra Schelstraete; Peter De Paepe; Sophie Vanhaesebrouck; Pieter A J G De Cock
Journal:  Int J Clin Pharm       Date:  2021-04-28

8.  Point-Counterpoint: Should Clinical Microbiology Laboratories Report Vancomycin MICs?

Authors:  Sara L Revolinski; Christopher D Doern
Journal:  J Clin Microbiol       Date:  2021-03-19       Impact factor: 5.948

9.  Comparison of the Predictive Performance Between Cystatin C and Serum Creatinine by Vancomycin via a Population Pharmacokinetic Models: A Prospective Study in a Chinese Population.

Authors:  Ren Zhang; Ming Chen; Tao-Tao Liu; Jie-Jiu Lu; Chun-le Lv
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2020-02       Impact factor: 2.441

Review 10.  Continuous Infusion Vancomycin in Pediatric Patients: A Critical Review of the Evidence.

Authors:  Heather L Girand
Journal:  J Pediatr Pharmacol Ther       Date:  2020
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.